Archive · 24 Jul 2025
Lupin Receives US FDA Approval for Diabetes Medications
Imagine a company called Lupin made copies of some medicines for diabetes.
The US government, the FDA, said it's okay to sell these medicines.
One medicine helps adults and kids with type 2 diabetes control their sugar levels.
It's like a copy of another medicine called Victoza.
The other medicine helps people who have very low blood sugar.
It's a copy of a medicine from Eli Lilly.
Both medicines will be made in India.
The company is happy to offer more options to help people with diabetes.
Lupin received USFDA approval for generic diabetes medications.
The approvals cover Liraglutide Injection and Glucagon for Injection.
Liraglutide is bioequivalent to Novo Nordisk's Victoza, for type 2 diabetes.
Glucagon is bioequivalent to Eli Lilly's product, treating severe hypoglycemia.
The drugs will be manufactured in Nagpur, India, and are estimated to generate substantial sales in the US.
- Who
- Lupin, a drug manufacturer, received approval from the US Food and Drug Administration (USFDA).
- What
- Lupin received USFDA approval for generic diabetes drugs.
- When
- The approval was received recently, and the news was published on July 24, 2025.
- Where
- The drugs will be manufactured in Nagpur, India, and sold in the US.
- Why
- The approvals allow Lupin to market generic versions of medications, expanding access to diabetes treatments.
- Company
- Lupin
- Regulatory Body
- USFDA
- Approved Drugs
- Liraglutide Injection, Glucagon for Injection
- Liraglutide Indication
- Type 2 diabetes
- Glucagon Indication
- Severe hypoglycemia
- Manufacturing Location
- Nagpur, India
- Liraglutide estimated US sales
- $458 million (annual)
- Glucagon estimated US sales
- $124 million (annual)